ProCE Banner Series

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

Join us for our live, 1-hour CME/CNE/CPE/AAPA-certified workshop series as we delve into the world of precision medicine for patients with lung or thyroid cancer. This series focuses on biomarker testing and targeted treatment strategies to enhance clinical outcomes for patients with NTRK fusion–positive and RET-altered disease.

To Register: Please click the green Learn More button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AAPA
  | ACPE
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for medical oncologists, pathologists, surgeons, interventional radiologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lung and thyroid cancer.

All Events

Past Events

November

20

2023

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

7:30 AM - 8:30 AM Mountain Time (MT)

Virtual

Private Event, Rio Rancho, New Mexico

December

06

2023

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in NY, Queens, New York

December

18

2023

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Virtual Event | Host Group in SC, Columbia, South Carolina

December

21

2023

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Virtual Event | Host Group in ID, Post Falls, Idaho

January

19

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

7:30 AM - 8:30 AM Eastern Time (ET)

Virtual

Virtual Event | Host Group in MI, Royal Oak, Michigan

January

22

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group Mob, MObile, Alabama

January

23

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event | Host Group in NY, Garden City, New York

January

25

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team

11:30 AM - 12:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in WDC, Washington, District of Columbia

February

08

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team [Open Registration]

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MD, Rockville, Maryland

February

20

2024

Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group TX, Decatur, Texas

Faculty

ProCE Banner Faculty
Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

ProCE Banner Faculty
Gerald Falchook, MD, MS

Director of Drug Development
Drug Development Unit
Sarah Cannon Research Institute (SCRI) at HealthONE
Presbyterian/St. Luke's Medical Center
Denver, Colorado

ProCE Banner Faculty
Rafael Santana-Davila, MD

Associate Professor
Fred Hutch Cancer Center/University of Washington
Seattle, Washington

ProCE Banner Faculty
Susan Scott, MD

Thoracic Medical Oncologist
Assistant Professor of Oncologist
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland

ProCE Banner Faculty
Vivek Subbiah, MD

Chief, Early-Phase Drug Development
Sarah Cannon Research Institute
Nashville, Tennessee

ProCE Banner Faculty
Vamsidhar Velcheti, MD

Professor of Medicine
NYU Grossman School of Medicine
Medical Director
Thoracic Oncology Program
Laura and Isaac Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
New York, New York 

ProCE Banner Faculty
Deborah J. Wong, MD, PhD

Associate Clinical Professor of Medicine
Division of Hematology/Oncology
UCLA Medical Center
Los Angeles, California

Topics

  • Welcome and Introduction
  • Overview of Rare Genomic Alterations in Thyroid Cancer and NSCLC and Rationale for Testing
  • Virtual Tumor Board Case Discussions:
    • Evidence-Based Testing Strategies to Detect Targetable Genomic Fusions and Mutations in Advanced NSCLC and Thyroid Cancer
    • TRK Inhibitors in the Care of Patients With NTRK-Altered NSCLC and Thyroid Cancer
    • RET Inhibitors in the Care of Patients With RET-Altered NSCLC and Thyroid Cancer
  • Summary and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners to optimize precision medicine approaches for patients with lung or thyroid cancer. 

Target Audience
This program is intended for medical oncologists, pathologists, surgeons, interventional radiologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lung and thyroid cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate guideline-recommended comprehensive genomic testing prior to treatment initiation to guide individualized therapy planning for patients with advanced or metastatic NSCLC and thyroid cancer
  • Apply clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate timely strategies for integrating TRK and RET inhibitors into the management of eligible patients with advanced or metastatic NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
  • Engage patients with advanced or metastatic NSCLC and thyroid cancer in shared decision-making to integrate patient preferences and goals into treatment planning

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-241-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Lilly.